A global leader in advanced cardiac monitoring and defibrillation products, Cardiac Science Corporation is the holder of over 100 patents relating to proprietary technology, devices and disposables. On 17th April, the company announced that it has been granted three new U.S. patents:

1) Patent No. 7,006,865: "Automatic Defibrillation Module for Integration with Standard Patient Monitoring Equipment"

A patent covering an external defibrillation module for integration into standard hospital patient monitors. The module has numerous modes of operation, including fully-automatic, and is designed for integration with generic patient monitoring equipment to share certain functions and provide patients with the appropriate anti-tachycardia therapy when needed.

2) Patent No. 6,993,386: "Public Access Defibrillation"
(A continuation, in part, of Cardiac Science's U.S. patent No. 6,658,290)

This patent covers a publicly-available portable defibrillator capable of being used by a bystander to automatically deliver life-saving defibrillation shock(s) to a heart attack victim.

3) Patent No. 6,983,183: "Method and Apparatus for Monitoring Cardiac Patients for T-Wave Alternans"

This patent covers a non-invasive testing method that employs a statistical analysis to identify microvolt abnormalities in a patient's electrocardiogram in order to determine a patient's vulnerability to sudden cardiac arrest (SCA).

These new patents are great additions to the company's entire collection of devices and technology which are cardiology-related products: Cardiac Science Corporation develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators, electrocardiographs, stress test systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, patient monitor- defibrillators and cardiology data management systems.

Source: Cardiac Science News